Media about us

• Atlas to invest in extra capacity at STI test manufacturing partner Bespak

  16 February 2017 Dani Bancroft / InPharma Technologist.com

  

  Atlas Genetics has said it will expand manufacturing capacity for cartridgebased STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.

• Liquid biopsies: The next frontier in cancer?

  15 February 2017 Ned Pagliarulo / BioPharmaDive

  

  As immuno-oncology dazzles and pharma companies race to develop new cancer medicines, a similar boom is underway to speed up and improve the detection of cancers.

• Top 5 Vendors in the Pharmerging Market from 2017 to 2021: Technavio

  01 February 2017 Yahoo Finance

  

  The pharmaceutical industry worldwide witnesses a dramatic regional shift to the pharmerging market, owing to the opportunities available. Considering the on-going trend of shift in global medicine dosage consumption to developing countries, about 55-60% of the global consumption should come from pharmerging markets by 2021. This will eventually lead to an incremental growth of around 25% from 2016 level.

• Struggling Marinus gets a bump out of a positive PhII snapshot

  24 January 2017 Arsalan Arif / Endpoints News

  

  A lit­tle more than six months since its stock price was crushed by a failed late-stage pro­gram for its lead­ing — and only — drug, tiny biotech mi­cro­cap Mar­i­nus $MRNS saw its shares shoot up this morn­ing after it of­fered a pos­i­tive Phase II snap­shot on a hand­ful of pa­tients who suf­fer from a rare ge­netic ail­ment.

• Marinus gets a lifeline with new ganaxolone data

  24 January 2017 Ben Adams / Fierce Biotech

  

  Micro cap Marinus Pharmaceuticals was up 28% premarket this morning on positive, early data from its midstage test of ganaxolone in a rare condition that causes severe seizures.

• JP Morgan Healthcare Conference, Day One: Genomic Health, Meridian Bioscience, Qiagen

  11 January 2017 Ed Winnick / GenomeWeb

  

  The 35th Annual JP Morgan Healthcare Conference began here Monday with several life science research tools and diagnostic firms making presentations to investors and other attendees.

• Epic uncovers prostate cancer biomarker

  09 January 2017 Lori Lesko / DDNEWS Cancer Research News

  

  Biotech company Epic Sciences’ focus on circulating tumor cells (CTCs) will not only advance the clinical use of liquid biopsies and improve how metastatic cancer is treated, it says, but also identified a unique CTC biomarker in patients with metastatic prostate cancer who respond to PARP inhibitors cancer drugs in development.

• Raindrop Vision Procedure Designed to Reduce or Eliminate Reading Glasses Now Available in Alabama.

  05 January 2017 PRWeb

  

  The All-New Raindrop® Near Vision Inlay is designed to improve near vision so you can once again see fine print, menus and your phone without the hassle of reading glasses.

• Pfizer Inc. Considerable Stocks on Returns- Horizon Pharma plc

  29 December 2016 Seneca Globe

  

  Pfizer Inc. (NYSE:PFE) , stock eased up around 0.15% in early session as its gaining volume of 11.21 Million. US pharma giant, Pfizer (NYSE:PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.

• Pfizer Inc. and NovaMedica have completed the last stage of negotiations

  29 December 2016 BM - Breaking News and Headlines

  

  Pfizer Inc. (NYSE:PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.